Product Details

Cefpodoxime + Clavulanic Acid Tablets BP 325 mg deliver a high-quality combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose combination manages bacterial infections caused by beta-lactamase-producing organisms, combining broad-spectrum cephalosporin coverage with beta-lactamase inhibition in a single tablet.

The tablets combine:

• Cefpodoxime, a third-generation cephalosporin antibiotic that eliminates bacteria by inhibiting bacterial cell wall synthesis, and
• Clavulanic Acid, a beta-lactamase inhibitor that protects Cefpodoxime from enzymatic breakdown by resistant bacteria, extending its antibacterial coverage.

Doctors commonly prescribe this combination for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other bacterial infections involving resistant organisms. Hospitals, clinics, and pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant combination therapy
• Treats bacterial infections from resistant, beta-lactamase-producing organisms
• Delivers combined cephalosporin and beta-lactamase inhibitor action
• Accurate 325 mg dosage per tablet
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, clinical, and pharmacy use